{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T19:50:37Z","timestamp":1789156237952,"version":"build-2803163510"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T00:00:00Z","timestamp":1698451200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T00:00:00Z","timestamp":1698451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2021QH050"],"award-info":[{"award-number":["ZR2021QH050"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Key Technology Research and Development Programme of China","award":["2022YFC2704200"],"award-info":[{"award-number":["2022YFC2704200"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The therapeutic effect of poly (ADP-ribose) polymerase inhibitors (PARPi) monotherapy compared with platinum-based chemotherapy, and the impact to subsequent platinum-based chemotherapy after PARPi resistance were inconclusive in breast cancer susceptibility genes (BRCA)1\/2-mutated ovarian cancer patients with secondary platinum-sensitive relapse.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>BRCA1\/2-mutated patients with secondary platinum-sensitive relapse included in this study did not receive any maintenance regimen after first- and second-line platinum-based chemotherapy, and the secondary platinum-free interval (PFI) was more than 6 months. Patients in study group were treated with PARPi monotherapy until disease progression, and patients in control group were treated with platinum-based chemotherapy without restriction. Progression-free survival (PFS) was defined as the time from third-line therapy to disease progression or death, PFS2 was defined as the time from platinum-based chemotherapy after PARPi resistance to next subsequent therapy or death. Post-recurrence survival (PRS) refers to the survival time after secondary platinum-sensitive relapse.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 119 patients were retrospectively analyzed, including 71 (59.7%) in study group and 48 (40.3%) in control group. The objective response rate (ORR: 77.5% vs. 80.0%, <jats:italic>p=<\/jats:italic>0.766) and PFS (median: 11.2 vs. 11.0 months, <jats:italic>p=<\/jats:italic>0.962) were comparable. The benefit of subsequent platinum-based chemotherapy after PARPi resistance was more pronounced in patients with PARPi treatment for more than 12 months (median PFS2: 8.6 vs. 4.3 months, <jats:italic>p=<\/jats:italic>0.040). PARPi monotherapy had no adverse effect on PRS compared with platinum-based chemotherapy (median PRS:41.2 vs. 42.8 months, <jats:italic>p=<\/jats:italic>0.323). Compared to patients in control group who had never received PARPi, PARPi monotherapy (median PRS: 41.2 vs. 33.7 months, <jats:italic>p=<\/jats:italic>0.019) and post-line treatment with PARPi in the control group (median PRS: 48.1 vs. 33.7 months, <jats:italic>p=<\/jats:italic>0.002) could prolong PRS for patients with secondary platinum-sensitive relapse.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>PARPi monotherapy was similar to platinum-based chemotherapy for BRCA1\/2-mutated ovarian cancer patients with secondary platinum-sensitive recurrence, and could improve prognosis.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13048-023-01283-2","type":"journal-article","created":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T03:24:08Z","timestamp":1698463448000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of poly (ADP-ribose) polymerase inhibitors monotherapy and the impact to subsequent platinum-based chemotherapy in breast cancer susceptibility genes1\/2-mutated ovarian cancer patients with secondary platinum-sensitive relapse"],"prefix":"10.1186","volume":"16","author":[{"given":"Yana","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiale","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hualei","family":"Bu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongwen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengjuan","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaorong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beihua","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingying","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,28]]},"reference":[{"issue":"1","key":"1283_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71(1):7\u201333.","journal-title":"CA Cancer J Clin."},{"key":"1283_CR2","doi-asserted-by":"crossref","unstructured":"Cheung A, Shah S, Parker J, Soor P, Limbu A, Sheriff M, et al. Non-Epithelial Ovarian Cancers: How Much Do We Really Know?. Int J Environ Res Public Health. 2022;19(3):1106.","DOI":"10.3390\/ijerph19031106"},{"issue":"10177","key":"1283_CR3","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/S0140-6736(18)32552-2","volume":"393","author":"S Lheureux","year":"2019","unstructured":"Lheureux S, Gourley C, Vergote I, Oza AM. Epithelial ovarian cancer. Lancet. 2019;393(10177):1240\u201353.","journal-title":"Lancet."},{"issue":"2","key":"1283_CR4","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.critrevonc.2006.03.004","volume":"60","author":"N Colombo","year":"2006","unstructured":"Colombo N, Van Gorp T, Parma G, Amant F, Gatta G, Sessa C, et al. Ovarian cancer. Crit Rev Oncol Hematol. 2006;60(2):159\u201379.","journal-title":"Crit Rev Oncol Hematol."},{"key":"1283_CR5","doi-asserted-by":"crossref","unstructured":"Shah S, Cheung A, Kutka M, Sheriff M, Boussios S. Epithelial Ovarian Cancer: Providing Evidence of Predisposition Genes. Int J Environ Res Public Health. 2022;19(13):8113.","DOI":"10.3390\/ijerph19138113"},{"issue":"9","key":"1283_CR6","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1002\/ijc.30633","volume":"140","author":"T Shi","year":"2017","unstructured":"Shi T, Wang P, Xie C, Yin S, Shi D, Wei C, et al. BRCA1 and BRCA2 mutations in ovarian cancer patients from China: ethnic-related mutations in BRCA1 associated with an increased risk of ovarian cancer. Int J Cancer. 2017;140(9):2051\u20139.","journal-title":"Int J Cancer."},{"issue":"11","key":"1283_CR7","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1158\/2159-8290.CD-15-0714","volume":"5","author":"PA Konstantinopoulos","year":"2015","unstructured":"Konstantinopoulos PA, Ceccaldi R, Shapiro GI, D\u2019Andrea AD. Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer. Cancer Discov. 2015;5(11):1137\u201354.","journal-title":"Cancer Discov."},{"key":"1283_CR8","doi-asserted-by":"crossref","unstructured":"Revythis A, Limbu A, Mikropoulos C, Ghose A, Sanchez E, Sheriff M, et al. Recent Insights into PARP and Immuno-Checkpoint Inhibitors in Epithelial Ovarian Cancer. Int J Environ Res Public Health. 2022;19(14):8577.","DOI":"10.3390\/ijerph19148577"},{"key":"1283_CR9","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer. Version 5.2022."},{"key":"1283_CR10","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer. Version 1.2023."},{"issue":"10","key":"1283_CR11","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1093\/annonc\/mds203","volume":"23","author":"LC Hanker","year":"2012","unstructured":"Hanker LC, Loibl S, Burchardi N, Pfisterer J, Meier W, Pujade-Lauraine E, et al. The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane\/platinum-based therapy. Ann Oncol. 2012;23(10):2605\u201312.","journal-title":"Ann Oncol."},{"issue":"2","key":"1283_CR12","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1634\/theoncologist.4-2-87","volume":"4","author":"MA Bookman","year":"1999","unstructured":"Bookman MA. Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy. Oncologist. 1999;4(2):87\u201394.","journal-title":"Oncologist."},{"issue":"9","key":"1283_CR13","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","volume":"18","author":"E Pujade-Lauraine","year":"2017","unstructured":"Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18(9):1274\u201384.","journal-title":"Lancet Oncol."},{"issue":"32","key":"1283_CR14","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.1200\/JCO.18.02238","volume":"37","author":"JM Del Campo","year":"2019","unstructured":"Del Campo JM, Matulonis UA, Malander S, Provencher D, Mahner S, Follana P, et al. Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16\/NOVA Trial. J Clin Oncol. 2019;37(32):2968\u201373.","journal-title":"J Clin Oncol."},{"issue":"2","key":"1283_CR15","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1097\/IGC.0b013e3182070f17","volume":"21","author":"GJ Rustin","year":"2011","unstructured":"Rustin GJ, Vergote I, Eisenhauer E, Pujade-Lauraine E, Quinn M, Thigpen T, et al. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer. 2011;21(2):419\u201323.","journal-title":"Int J Gynecol Cancer."},{"issue":"11","key":"1283_CR16","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1002\/humu.20880","volume":"29","author":"SE Plon","year":"2008","unstructured":"Plon SE, Eccles DM, Easton D, Foulkes WD, Genuardi M, Greenblatt MS, et al. Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum Mutat. 2008;29(11):1282\u201391.","journal-title":"Hum Mutat."},{"issue":"5","key":"1283_CR17","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405\u201324.","journal-title":"Genet Med."},{"key":"1283_CR18","doi-asserted-by":"crossref","unstructured":"Shah S, Rachmat R, Enyioma S, Ghose A, Revythis A, Boussios S. BRCA Mutations in Prostate Cancer: Assessment, Implications and Treatment Considerations. Int J Mol Sci. 2021;22(23):12628.","DOI":"10.3390\/ijms222312628"},{"issue":"1","key":"1283_CR19","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12943-020-01167-9","volume":"19","author":"H Zhu","year":"2020","unstructured":"Zhu H, Wei M, Xu J, Hua J, Liang C, Meng Q, et al. PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications. Mol Cancer. 2020;19(1):49.","journal-title":"Mol Cancer."},{"issue":"5","key":"1283_CR20","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/S1470-2045(19)30029-4","volume":"20","author":"KN Moore","year":"2019","unstructured":"Moore KN, Secord AA, Geller MA, Miller DS, Cloven N, Fleming GF, et al. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2019;20(5):636\u201348.","journal-title":"Lancet Oncol."},{"issue":"2","key":"1283_CR21","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.ygyno.2015.12.020","volume":"140","author":"SM Domchek","year":"2016","unstructured":"Domchek SM, Aghajanian C, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, et al. Efficacy and safety of olaparib monotherapy in germline BRCA1\/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy. Gynecol Oncol. 2016;140(2):199\u2013203.","journal-title":"Gynecol Oncol."},{"issue":"2","key":"1283_CR22","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.ygyno.2017.08.022","volume":"147","author":"AM Oza","year":"2017","unstructured":"Oza AM, Tinker AV, Oaknin A, Shapira-Frommer R, McNeish IA, Swisher EM, et al. Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2. Gynecol Oncol. 2017;147(2):267\u201375.","journal-title":"Gynecol Oncol."},{"issue":"11","key":"1283_CR23","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1200\/JCO.19.02745","volume":"38","author":"RT Penson","year":"2020","unstructured":"Penson RT, Valencia RV, Cibula D, Colombo N, Leath CA 3rd, Bidzinski M, et al. Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1\/2 Mutation (SOLO3): A Randomized Phase III Trial. J Clin Oncol. 2020;38(11):1164\u201374.","journal-title":"J Clin Oncol."},{"issue":"1","key":"1283_CR24","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S1470-2045(16)30559-9","volume":"18","author":"EM Swisher","year":"2017","unstructured":"Swisher EM, Lin KK, Oza AM, Scott CL, Giordano H, Sun J, et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol. 2017;18(1):75\u201387.","journal-title":"Lancet Oncol."},{"issue":"34","key":"1283_CR25","doi-asserted-by":"publisher","first-page":"5530","DOI":"10.1200\/JCO.2008.16.1703","volume":"26","author":"DS Tan","year":"2008","unstructured":"Tan DS, Rothermundt C, Thomas K, Bancroft E, Eeles R, Shanley S, et al. \u201cBRCAness\u201d syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol. 2008;26(34):5530\u20136.","journal-title":"J Clin Oncol."},{"key":"1283_CR26","doi-asserted-by":"crossref","unstructured":"Boussios S, Rassy E, Moschetta M, Ghose A, Adeleke S, Sanchez E, et al. BRCA Mutations in Ovarian and Prostate Cancer: Bench to Bedside. Cancers (Basel). 2022;14(16):3888.","DOI":"10.3390\/cancers14163888"},{"key":"1283_CR27","doi-asserted-by":"crossref","unstructured":"McMullen M, Karakasis K, Madariaga A, Oza AM. Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian Cancer. Cancers (Basel). 2020;12(6):1607.","DOI":"10.3390\/cancers12061607"},{"issue":"19","key":"1283_CR28","doi-asserted-by":"publisher","first-page":"5485","DOI":"10.1158\/1078-0432.CCR-13-1262","volume":"19","author":"JE Ang","year":"2013","unstructured":"Ang JE, Gourley C, Powell CB, High H, Shapira-Frommer R, Castonguay V, et al. Efficacy of chemotherapy in BRCA1\/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study. Clin Cancer Res. 2013;19(19):5485\u201393.","journal-title":"Clin Cancer Res."},{"issue":"15_suppl","key":"1283_CR29","doi-asserted-by":"publisher","first-page":"5563","DOI":"10.1200\/JCO.2021.39.15_suppl.5563","volume":"39","author":"R Brann","year":"2021","unstructured":"Brann R, Kremer KM, Carlson M, LoCoco S, Lea JS, Miller DS, et al. Outcomes of ovarian cancer patients treated with platinum or non-platinum based chemotherapy after PARP inhibitor maintenance. J Clin Oncol. 2021;39(15_suppl):5563.","journal-title":"J Clin Oncol"},{"key":"1283_CR30","doi-asserted-by":"crossref","unstructured":"Ghose A, Gullapalli SVN, Chohan N, Bolina A, Moschetta M, Rassy E, et al. Applications of Proteomics in Ovarian Cancer: Dawn of a New Era. Proteomes. 2022;10(2):16.","DOI":"10.3390\/proteomes10020016"},{"issue":"6","key":"1283_CR31","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1002\/cncr.24149","volume":"115","author":"A du Bois","year":"2009","unstructured":"du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d\u2019Investigateurs Nationaux Pour les Etudes des Cancers de l\u2019Ovaire (GINECO). Cancer. 2009;115(6):1234\u201344.","journal-title":"Cancer."},{"issue":"1","key":"1283_CR32","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ygyno.2015.11.009","volume":"140","author":"J Kotsopoulos","year":"2016","unstructured":"Kotsopoulos J, Rosen B, Fan I, Moody J, McLaughlin JR, Risch H, et al. Ten-year survival after epithelial ovarian cancer is not associated with BRCA mutation status. Gynecol Oncol. 2016;140(1):42\u20137.","journal-title":"Gynecol Oncol."},{"issue":"8","key":"1283_CR33","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1097\/IGC.0000000000001065","volume":"27","author":"X Wu","year":"2017","unstructured":"Wu X, Wu L, Kong B, Liu J, Yin R, Wen H, et al. The First Nationwide Multicenter Prevalence Study of Germline BRCA1 and BRCA2 Mutations in Chinese Ovarian Cancer Patients. Int J Gynecol Cancer. 2017;27(8):1650\u20137.","journal-title":"Int J Gynecol Cancer."}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-023-01283-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13048-023-01283-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-023-01283-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T03:26:23Z","timestamp":1698463583000},"score":1,"resource":{"primary":{"URL":"https:\/\/ovarianresearch.biomedcentral.com\/articles\/10.1186\/s13048-023-01283-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,28]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1283"],"URL":"https:\/\/doi.org\/10.1186\/s13048-023-01283-2","relation":{},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,28]]},"assertion":[{"value":"29 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was based on the statement of ethical principles in the Declaration of Helsinki. The Medical Ethics Committee of Qilu Hospital of Shandong University approved this study (KYLL-2017-133) on February 21, 2017. The study protocol was approved by the ethical review boards of the participating institutions, and signed consent was obtained from each patient.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"No conflict.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"209"}}